Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVIG vs Zidovudine in HIV-Infected Infants
NCT00000961Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- May 1991
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial of anti-HIV immune serum globulin in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and Tolerance of HIVIG and Zidovudine at 48 weeks. Status: terminated.
02
Drugs
anti-HIV immune serum globulin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000961.